Literature DB >> 3436340

Hydrolysis of haloperidol decanoate in vitro by cultured cells.

Y Oh-e1, H Miyazaki, Y Matsunaga, K Nambu, N Kobayashi, M Hashimoto.   

Abstract

[14C]Haloperidol decanoate was hydrolysed by partially purified carboxylesterase but not in plasma, blood, lymph and lymphatic liquid. These fluids inhibited the enzyme-mediated hydrolysis of the ester. Within the same incubation period as above, the ester was found hydrolysed to various extents in cell cultures of isolated rat liver cells, of human and rat lymphocytes and of established cell lines (BGM cells, WI-38 cells and L6 cells). Thus, the hydrolysis of the ester was demonstrated in vitro with use of viable cell cultures instead of enzyme preparation. From the time course study on the metabolism of haloperidol decanoate in cell cultures, it was concluded that haloperidol decanoate was first concentrated in the cells and hydrolysed to haloperidol. Based on these results, the metabolic sequences in vivo leading to the formation of active principle haloperidol after intramuscular administration of its decanoate were discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436340     DOI: 10.1007/BF03189895

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat.

Authors:  J L BOLLMAN; J C CAIN; J H GRINDLAY
Journal:  J Lab Clin Med       Date:  1948-10

Review 2.  The long-acting neuroleptics: a retrospective appraisal.

Authors:  H L Yale
Journal:  Drug Metab Rev       Date:  1978       Impact factor: 4.518

3.  [Syntheses of [Carboxyl-14C]etofenamate and its major metabolite].

Authors:  T Negoro; M Nakao; A Kagemoto; M Hashimoto
Journal:  Radioisotopes       Date:  1982-12

Review 4.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

5.  Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins.

Authors:  K Nambu; H Miyazaki; Y Nakanishi; Y Oh-e; Y Matsunaga; M Hashimoto
Journal:  Biochem Pharmacol       Date:  1987-05-15       Impact factor: 5.858

6.  Identical binding properties of (+/-)- and (-)-125Iodocyanopindolol to beta 2-adrenoceptors in intact human lymphocytes.

Authors:  N O'Hara; O E Brodde
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-11

7.  Absorption of intramuscularly administered [14C]haloperidol decanoate in rats.

Authors:  Y Matsunaga; K Nambu; Y Oh-e; H Miyazaki; M Hashimoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jul-Sep       Impact factor: 2.441

8.  Excretion and metabolism of intramuscularly administered [14C]-haloperidol decanoate in rats.

Authors:  Y Matsunaga; K Nambu; Y Oh-e; H Miyazaki; M Hashimoto
Journal:  Arzneimittelforschung       Date:  1986-03

9.  Disposition and metabolism of [14C]-haloperidol in rats.

Authors:  H Miyazaki; Y Matsunaga; K Nambu; Y Oh-e; K Yoshida; M Hashimoto
Journal:  Arzneimittelforschung       Date:  1986-03

10.  Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.

Authors:  R Deberdt; P Elens; W Berghmans; J Heykants; R Woestenborghs; F Driesens; A Reyntjens; I van Wijngaarden
Journal:  Acta Psychiatr Scand       Date:  1980-10       Impact factor: 6.392

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.